"Hep G2人肝癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

【細(xì)胞培養(yǎng)經(jīng)驗(yàn)分享】啟蒙老師的重要性：一般進(jìn)實(shí)驗(yàn)室都有師兄師姐帶著做，他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則，如營養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開蓋手法、細(xì)胞吹打手法等等。要學(xué)會(huì)他們的正確操作，在第一次的時(shí)候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞，細(xì)胞有時(shí)真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時(shí)解決這些意外，避免重復(fù)實(shí)驗(yàn)帶來的更大痛苦。好細(xì)胞要及時(shí)保種：細(xì)胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn)，有一次細(xì)胞污染了，全軍覆沒。當(dāng)時(shí)可后悔沒有保種。細(xì)胞跟人一樣，不同的細(xì)胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細(xì)細(xì)體會(huì)，不同細(xì)胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

KU-812F Cells;背景說明：慢性粒細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：E304細(xì)胞、LAN-6細(xì)胞、BpRc1細(xì)胞

PCI-4M Cells;背景說明：喉鱗癌；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：hTERT RPE1細(xì)胞、52PE細(xì)胞、WM451Lu細(xì)胞

Hs746-T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DU 4475細(xì)胞、NCI-H2126細(xì)胞、KY-270細(xì)胞

Hep G2人肝癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：是一種人肝癌細(xì)胞系，是來自15歲男性白人的組織，該患者患有高度分化的肝細(xì)胞癌；Hep G2細(xì)胞形態(tài)為上皮細(xì)胞樣，模式染色體數(shù)為55；Hep G2細(xì)胞在免疫抑制小鼠中不致瘤。

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

絕大部分細(xì)胞消化只要用胰酶潤洗一遍即可：吸去胰酶后，殘留的那些無法計(jì)算體積的附著在細(xì)胞表面的微量胰酶在37℃一般不到2min足夠消化細(xì)胞(絕大部分1min不到)。對(duì)于這些細(xì)胞原則上不要用胰酶孵育細(xì)胞，連續(xù)這樣傳代，對(duì)細(xì)胞傷害很大。簡(jiǎn)單的程序是PBS潤洗吸去，胰酶潤洗吸去，然后37℃消化。什么算是消化好了呢？不需要把細(xì)胞全部消化成間隔分布很離散的單個(gè)圓形才算消化好了，一般你肉眼觀察貼壁細(xì)胞層，只要能移動(dòng)了，多半呈沙狀移動(dòng)，其實(shí)已經(jīng)是可以了。一般能移動(dòng)了，說明細(xì)胞與培養(yǎng)基質(zhì)材料的附著已經(jīng)消失了，細(xì)胞之間的附著也已經(jīng)消失了，細(xì)胞已經(jīng)獨(dú)立分布了(雖然沒有呈現(xiàn)很廣的離散分布)。這個(gè)時(shí)候應(yīng)該停止消化，不要等到看到鏡下所有細(xì)胞都分離得非常好，間隙很大，才停止。細(xì)胞系在貼壁的過程中仍然會(huì)聚集，這個(gè)是貼壁培養(yǎng)的細(xì)胞，尤其是腫瘤細(xì)胞的一個(gè)特性，你可以嘗試，準(zhǔn)備100%的單個(gè)細(xì)胞懸液，貼壁后觀察細(xì)胞，仍然是幾個(gè)幾個(gè)細(xì)胞聚集在一起。一些懸浮培養(yǎng)細(xì)胞也是如此，容易聚集，不要過幾個(gè)小時(shí)就拿出來吹打成單細(xì)胞懸液。細(xì)胞只要能從基質(zhì)上脫離下來，即使是成片的(比如Calu-3細(xì)胞)，吹打不超過20次(一般10次即可)，成小規(guī)模聚集(10個(gè)細(xì)胞左右)是正常的，不要再去延長消化時(shí)間，等待單細(xì)胞懸液出現(xiàn)。比較難消化的細(xì)胞：潤洗方法5min還不能消化，以結(jié)腸癌細(xì)胞為例，比如：HCT15、LS411和KM12細(xì)胞，胰酶消化，一般10 cm培養(yǎng)皿，一次加入300ul-500ul就足夠了。即使這樣難消化的細(xì)胞，一般不超過5min，即可見細(xì)胞成片移動(dòng)，就應(yīng)該停止消化。一些正常細(xì)胞也會(huì)有難消化的時(shí)候，比如tsDC細(xì)胞，用胰酶孵育，3min左右即可看到成片沙狀移動(dòng)。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

Hep G2人肝癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

H1417 Cells;背景說明：小細(xì)胞肺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Jiyoye細(xì)胞、GM03671C細(xì)胞、GM2131細(xì)胞

RCC-10 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKCO-1細(xì)胞、OCI-Ly 18細(xì)胞、NCIH1355細(xì)胞

TE-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：OC316細(xì)胞、Sf-21細(xì)胞、HCC-1395細(xì)胞

SW 48 Cells;背景說明：１９７１-１９７５年間，A. Leibovitz從結(jié)腸腺癌中分離建立十個(gè)細(xì)胞系，SW４８為為其中之一。該細(xì)胞合成癌胚抗原，能在裸鼠中成瘤。;傳代方法：１：３傳代,２-３天傳一代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HCe-8693細(xì)胞、MFHL-2細(xì)胞、Detroit-562細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞復(fù)蘇后貼壁細(xì)胞較少的問題分析：總結(jié)１：復(fù)蘇過程沒有問題，是否是從拿出直接放入溫水，還有培養(yǎng)箱，二氧化碳濃度，培養(yǎng)基、PH值等環(huán)節(jié)。要么加GAO濃度FBS １５-２０%，看看能否幫助貼壁，當(dāng)然也需要考慮血清問題，還有確信拿來的細(xì)胞沒問題。總結(jié)２：首先應(yīng)該懷疑凍存，實(shí)際上復(fù)蘇出問題的可能非常小，因?yàn)椴僮骱?jiǎn)單，而且死板。１、你凍存的時(shí)候是不是消化的時(shí)間過長，這是一般人所注意不到的，即使書上也不講這個(gè)問題，太長的消化時(shí)間會(huì)讓細(xì)胞復(fù)蘇時(shí)失去貼壁能力，表現(xiàn)為先貼后死，原因是在你復(fù)蘇的時(shí)候細(xì)胞已進(jìn)入凋亡程序，不可逆轉(zhuǎn)的死亡。２、你的凍存HAO不HAO，是什么，甘油還是DMSO，質(zhì)量非常重要，否則也會(huì)死亡。３、你的凍存的量加的是不是太多，AC推薦是不超過７%，大于５%，太多也不HAO。４、你在凍存的時(shí)候是不是把DMSO混均勻，這個(gè)有一些影響，但不算太大。５、你的凍存是否按部就班，就是所溫度梯度是不是把握嚴(yán)格，很多人容易忘卻這個(gè)事情，因?yàn)檫@個(gè)東西流程長。６、如果你細(xì)胞污染，你是否能很快看到，我比我的導(dǎo)師能早一天看到污染。從這個(gè)角度講建議去除離心這步。７、你的細(xì)胞在凍存前是否過密。還有，不贊成孵箱污染這個(gè)概念的，所有在一個(gè)孵箱里的細(xì)胞都污染一個(gè)細(xì)菌的話，這個(gè)細(xì)菌是源于孵箱的，但這不代表孵箱污染，因?yàn)榉跸錈o論你如何處理都有大量的細(xì)菌，問題在操作。每次污染的原因都要盡可能的找，以后就不犯同樣的問題，這個(gè)很重要，不能靠猜，否則你就有可能細(xì)胞養(yǎng)絕Zui后換課題，這個(gè)見得太多了，別不當(dāng)會(huì)事。

HSC-1 Cells;背景說明：皮膚鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：293 H細(xì)胞、HOP 62細(xì)胞、WI-38細(xì)胞

FT-293 Cells;背景說明：該細(xì)胞穩(wěn)定表達(dá)SV４０大T抗原，并且促進(jìn)最適病毒產(chǎn)物的產(chǎn)生。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：圓形;相關(guān)產(chǎn)品有：B104 [Rat neuroblastoma]細(xì)胞、ARH-77細(xì)胞、NPA87-1細(xì)胞

bEnd3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI-LY-7細(xì)胞、T 98 G細(xì)胞、HEL9217細(xì)胞

CORL279 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MILE SVEN1細(xì)胞、SR細(xì)胞、U87 MG細(xì)胞

NCIH1734 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SUDHL-1細(xì)胞、NCI-H1395細(xì)胞、SW-403細(xì)胞

OCI Ly3 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Tokyo Medical and Dental university 8細(xì)胞、MDAMB436細(xì)胞、CESS細(xì)胞

Malme-3M Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長特性：混合生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：NCI-H920細(xì)胞、HEK-EBNA細(xì)胞、Hs 343.T細(xì)胞

EFO27 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH2171細(xì)胞、H1417細(xì)胞、Balb/c 3T3細(xì)胞

NCI-H2198 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ca761細(xì)胞、OVCAR5細(xì)胞、DSL6A/C1細(xì)胞

CCC-HIE-2 Cells;背景說明：胚胎；腸粘膜;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEK293EBNA細(xì)胞、293 H細(xì)胞、Gejiu Lung Carcinoma-82細(xì)胞

U-87 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LLC-WRC 256細(xì)胞、TE-12細(xì)胞、McArdle RH-7777細(xì)胞

U-138 MG Cells;背景說明：星形細(xì)胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH196細(xì)胞、A549/DDP細(xì)胞、VMRCRCZ細(xì)胞

HGBEC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BEAS-2B細(xì)胞、MGH-U1 (EJ)細(xì)胞、LNCaP C4-2B細(xì)胞

BRL3A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WEHI-164細(xì)胞、NTera-2D1細(xì)胞、COLO-205細(xì)胞

Panc02-H0 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PANC-08-13細(xì)胞、Y-1細(xì)胞、VA-ES-BJ細(xì)胞

4T1-LUC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEL-92.1.7細(xì)胞、BT-325細(xì)胞、H650細(xì)胞

OCILY3 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Madison細(xì)胞、mouse Inner Medullary Collecting Duct-3細(xì)胞、HEK AD293細(xì)胞

Abcam A-549 TXNRD1 KO Cells(提供STR鑒定圖譜)

AG03511 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line CSH870 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RST130 Cells(提供STR鑒定圖譜)

BEP2D H1ATN Cells(提供STR鑒定圖譜)

CHO-tsH1-C11B6 Cells(提供STR鑒定圖譜)

DA02919 Cells(提供STR鑒定圖譜)

EndoC-betaH2 Cells(提供STR鑒定圖譜)

GM06013 Cells(提供STR鑒定圖譜)

JROECL 19 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：BI-Mel細(xì)胞、KRC Y細(xì)胞、HBSMC細(xì)胞

Hep G2人肝癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

OVCAR420 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SiHa細(xì)胞、MDA MB 134VI細(xì)胞、SF767細(xì)胞

NK-92 MI Cells;背景說明：NK細(xì)胞；淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H2291細(xì)胞、GP293細(xì)胞、BE(2)M17細(xì)胞

B16/F0 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：P3/ag細(xì)胞、SW-839細(xì)胞、ATN1細(xì)胞

CCRF-CEM C1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HIMEC細(xì)胞、FaDu細(xì)胞、HCT-GEO細(xì)胞

GH3 Cells;背景說明：GH３細(xì)胞系是由TashjianAH等在１９６５年７月從一只７月齡的雌性Wistar-Furth大鼠的垂體腫瘤中分離建立的。GH３細(xì)胞系不是直接來源于GH１細(xì)胞系的克隆，而是從原代培養(yǎng)的GH１細(xì)胞在大鼠身上傳代兩次形成的腫瘤中建立的。上皮樣的GH３細(xì)胞比GH１分泌更高水平的生長激素，也可產(chǎn)生催乳素。對(duì)調(diào)控GH３細(xì)胞分泌蛋白類激素的研究表明，化可的松可以刺激生長激素的分泌、抑制催乳素的產(chǎn)生。;傳代方法：１：２傳代;生長特性：疏松貼壁，有漂浮的細(xì)胞簇;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：UPCI-SCC090細(xì)胞、HCT15細(xì)胞、293T細(xì)胞

ABLS-1 Cells(提供STR鑒定圖譜)

HEp-2 Cells;背景說明：最初認(rèn)為這個(gè)細(xì)胞源自喉上皮癌，但隨后通過同功酶分析、HeLa標(biāo)記染色體和DNA指紋分析發(fā)現(xiàn)，起源細(xì)胞已被HeLa污染。 角蛋白免疫過氧化物酶染色陽性。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Jurkat-E6細(xì)胞、HCC38細(xì)胞、beta TC6細(xì)胞

H-1734 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：JM-1細(xì)胞、3T3NIH細(xì)胞、HBL-100細(xì)胞

U-343-MG Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OUMS-27細(xì)胞、CMT 93細(xì)胞、H1568細(xì)胞

5-8F Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs852細(xì)胞、TE1細(xì)胞、NCI-H1417細(xì)胞

SKOV-3 Cells;背景說明：SK-OV-３由G.Trempe和L.J.Old在１９７３年從卵巢腫瘤病人的腹水分離得到。 此細(xì)胞對(duì)腫瘤壞死因子和幾種細(xì)胞毒性藥物包括白喉毒素、順鉑和阿霉素均耐受。 在裸鼠中致瘤，且形成與卵巢原位癌一致的中度分化的腺癌。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MOLT 3細(xì)胞、MADB-106細(xì)胞、G-292細(xì)胞

H-28 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH2126細(xì)胞、NCI-H2228細(xì)胞、UACC-812細(xì)胞

JEG-3 Cells;背景說明：這是一株超三倍體人類細(xì)胞株;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H-295R細(xì)胞、GM02131A細(xì)胞、Shadyside Hospital Pittsburgh-77細(xì)胞

SKNEP Cells;背景說明：超微結(jié)構(gòu)有少許微絨毛，連接復(fù)合物，形態(tài)完整的高爾基體，內(nèi)質(zhì)網(wǎng)多為光滑型，脂滴，沒有病毒棵粒。;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：半貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：U-138MG細(xì)胞、U14細(xì)胞、BIC1細(xì)胞

GS-109-V-20 Cells(提供STR鑒定圖譜)

HAP1 PPARD (-) 2 Cells(提供STR鑒定圖譜)

U-343MG Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-SNU-601細(xì)胞、SW480E細(xì)胞、DB細(xì)胞

GDM-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：MCF7-GFP細(xì)胞、B16 melanoma F10細(xì)胞、UWB1289細(xì)胞

OVCAR.8 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-446細(xì)胞、HCM細(xì)胞、IPLB-Sf21AE細(xì)胞

C-Lu65 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：１０傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：MOLP-2細(xì)胞、RCC10細(xì)胞、NCIH2009細(xì)胞

Panc 10.05 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：U373-MG細(xì)胞、CMT-93細(xì)胞、SNUC2A細(xì)胞

Mouse Bladder Tumor line-2 Cells;背景說明：膀胱移行細(xì)胞癌；C３H/He;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NPA87-1細(xì)胞、Porcine Kidney-15細(xì)胞、IPLB-SF-21細(xì)胞

MM1.S Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：混合生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：TKB1細(xì)胞、LM8細(xì)胞、V-79細(xì)胞

A704 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：４傳代，每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：VP229細(xì)胞、HFLS細(xì)胞、Hs606細(xì)胞

hTERT SMC PM151T Cells(提供STR鑒定圖譜)

KTCTL-1M Cells(提供STR鑒定圖譜)

MRC-5-50 Cells(提供STR鑒定圖譜)

NZW-S1-M Cells(提供STR鑒定圖譜)

RKID001 Cells(提供STR鑒定圖譜)

Ubigene HEK293 EGFR KO Cells(提供STR鑒定圖譜)

WG0680 Cells(提供STR鑒定圖譜)

HC11-C24 Cells(提供STR鑒定圖譜)

SH-SY5Y Cells;背景說明：據(jù)報(bào)道，該細(xì)胞的密度可高達(dá)１×１０６cells/cm２，具有中等水平的多巴胺β羥化酶的活性。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HMEC1細(xì)胞、COR L279細(xì)胞、ES-2細(xì)胞

CCD19-Lu Cells;背景說明：肺成纖維細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UCD-MLA-144細(xì)胞、NG 108-15細(xì)胞、AAV-293細(xì)胞

6-10B Cells;背景說明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-ChA-1細(xì)胞、OVCA8細(xì)胞、SU-86-86細(xì)胞

H-748 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長 ;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Mel624細(xì)胞、MARC 145細(xì)胞、SK-RC 39細(xì)胞

Colon38 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H125細(xì)胞、RC13細(xì)胞、JF305細(xì)胞

Colon38 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H125細(xì)胞、RC13細(xì)胞、JF305細(xì)胞

SCL2 Cells;背景說明：皮膚鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MD Anderson-Metastatic Breast-415細(xì)胞、4175細(xì)胞、TFK-1細(xì)胞

MN9D Cells;背景說明：多巴胺能神經(jīng)元 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U251n細(xì)胞、Vero from pool #76細(xì)胞、HAPI細(xì)胞

KE37 Cells;背景說明：急性T淋巴細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H2107細(xì)胞、J111細(xì)胞、M14細(xì)胞

Mouse Podocyte Clone-5 Cells;背景說明：腎足細(xì)胞；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DSL-6A/C1細(xì)胞、HCEC-12細(xì)胞、U-251細(xì)胞

CORL279 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MILE SVEN1細(xì)胞、SR細(xì)胞、U87 MG細(xì)胞

COS7 Cells;背景說明：此細(xì)胞株源自CV-１細(xì)胞株，經(jīng)轉(zhuǎn)染起始點(diǎn)缺失的SV４０病毒突變體得到；編碼表達(dá)野生型T抗原，所以該細(xì)胞適合作為需要SV４０T抗原表達(dá)的載體的轉(zhuǎn)染宿主。該細(xì)胞表達(dá)T抗原，允許SV４０病毒的溶解性生長，支持４０℃時(shí)溫度敏感性A２０９病毒的復(fù)制，支持起始區(qū)域缺陷的SV４０突變體的復(fù)制。因含有SV４０病毒的DNA序列，該細(xì)胞需要在２級(jí)生物安全柜中操作。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：BALB/3T3 cl. A31細(xì)胞、HR1K細(xì)胞、Vx2細(xì)胞

NOZAWA Cells;背景說明：患者有癌性腹膜炎。細(xì)胞為中等分化的管狀膽囊癌。會(huì)分泌AFP和CEA。倍增時(shí)間４８小時(shí)，板植率１４-１９%。細(xì)胞可在裸鼠中成瘤，形態(tài)與原發(fā)腫瘤相似。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：ME180細(xì)胞、NCI-SNU-878細(xì)胞、HepaRG細(xì)胞

Hs 683.T Cells;背景說明：該細(xì)胞源自７６歲白人男性的左顳葉側(cè)膠質(zhì)瘤組織，有微絨毛，無橋粒。 ;傳代方法：１：４傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：TPC1細(xì)胞、RPTC細(xì)胞、HS5細(xì)胞

4T1.2 Cells;背景說明：乳腺癌；雌性；BALB/cfC３H;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SHG-44細(xì)胞、143 B細(xì)胞、Colon26細(xì)胞

SW-OH1 Cells(提供STR鑒定圖譜)

686LN-M4e Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HSC-2細(xì)胞、Dx5細(xì)胞、786-O RCC細(xì)胞

QG-56 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SY5Y細(xì)胞、Tu-686細(xì)胞、SB細(xì)胞

VERO76 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：AN3CA細(xì)胞、SCC090細(xì)胞、CAKI.1細(xì)胞

HEK/293 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：VMM5A細(xì)胞、Human Corneal Epithelial cells-Transformed細(xì)胞、L-M[TK-]細(xì)胞

LM(TK-) Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC0015細(xì)胞、373 MG細(xì)胞、B/C3T3細(xì)胞

Sci-1 Cells;背景說明：胚胎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Anip-973細(xì)胞、EC-9706細(xì)胞、ECC 10細(xì)胞

Hep G2人肝癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

NPA87-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUM 52PE細(xì)胞、Y3細(xì)胞、HT 1376細(xì)胞

HH [Human lymphoma] Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NCIH1184細(xì)胞、H-1882細(xì)胞、C2A細(xì)胞

BrCL18 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MUTZ3細(xì)胞、SKMEL-2細(xì)胞、VK-2/E6E7細(xì)胞

H1954 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Eca109細(xì)胞、KNS-42細(xì)胞、HO-8910PM細(xì)胞

JIMT Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HECV細(xì)胞、A1847細(xì)胞、MDA-MB-157細(xì)胞

Hs688(A)T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：WM266-4細(xì)胞、NIH:OVCAR-10細(xì)胞、HT 1197細(xì)胞

J774A1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Centre Antoine Lacassagne-148細(xì)胞、P388細(xì)胞、MSB-1細(xì)胞

alphaTC1 Clone 6 Cells;背景說明：胰島素瘤；a細(xì)胞；C５７BL/６xDBA/２;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WM115mel細(xì)胞、WiDr細(xì)胞、SK-N-BE(1)n細(xì)胞

BayGenomics ES cell line RRS098 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YTA357 Cells(提供STR鑒定圖譜)

iBMK D3.Hras-1RED-10 Cells(提供STR鑒定圖譜)

PCRP-ORC1-1C4 Cells(提供STR鑒定圖譜)

irPSCc2 Cells(提供STR鑒定圖譜)

HPSI0516i-yibc_4 Cells(提供STR鑒定圖譜)

" "Patent=US4393133

Knowles B.B., Aden D.P.

Human hepatoma derived cell line, process for preparation thereof, and uses therefor.

Patent number US4393133, 12-Jul-1983

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x

Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J., Revillard J.-P.

Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.

Eur. J. Biochem. 165:699-704(1987)

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613

Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.

Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.

FASEB J. 7:1407-1413(1993)

PubMed=8384076; DOI=10.1016/0165-4608(93)90227-D

Chen H.-L., Chiu T.-S., Chen P.-J., Chen D.-S.

Cytogenetic studies on human liver cancer cell lines.

Cancer Genet. Cytogenet. 65:161-166(1993)

PubMed=8389256; DOI=10.1093/carcin/14.5.987

Hsu I.-C., Tokiwa T., Bennett W.P., Metcalf R.A., Welsh J.A., Sun T.-T., Harris C.C.

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Carcinogenesis 14:987-992(1993)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163

Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.

Mutations and altered expression of p16INK4 in human cancer.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x; PMCID=PMC1534706

Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.

HLA expression in hepatocellular carcinoma cell lines.

Clin. Exp. Immunol. 97:328-333(1994)

PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A

Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K., Kosaka T., Tsuji T., Namba M.

Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.

J. Med. Virol. 48:133-140(1996)

DOI=10.11418/jtca1981.16.3_173

Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ohashi R., Namba M.

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108

Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

Cell. Immunol. 177:176-181(1997)

PubMed=9359923; DOI=10.18926/AMO/30789

Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ishioka C., Namba M.

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Acta Med. Okayama 51:261-265(1997)

PubMed=11050057; DOI=10.1053/jhep.2000.19349

Wong N., Lai P.B.-S., Pang E., Leung T.W.-T., Lau J.W.-Y., Johnson P.J.

A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.

Hepatology 32:1060-1068(2000)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11981770; DOI=10.1053/jhep.2002.32668

Clemens D.L., Forman A., Jerrells T.R., Sorrell M.F., Tuma D.J.

Relationship between acetaldehyde levels and cell survival in ethanol-metabolizing hepatoma cells.

Hepatology 35:1196-1204(2002)

PubMed=12029633; DOI=10.1053/jhep.2002.33683

Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Hepatology 35:1476-1484(2002)

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

DOI=10.1385/CP:1:3-4:313

Pang R.T.-K., Poon T.C.-W., Wong N., Lai P.B.-S., Wong N.L.-Y., Chan C.M.-L., Yu J.W.S., Chan A.T.-C., Sung J.J.-Y.

Comparison of protein expression patterns between hepatocellular carcinoma cell lines and a hepatoblastoma cell line.

Clin. Proteomics 1:313-331(2004)

PubMed=14980111

Zhai B.-J., Wu F., Shao Z.-Y., Hu K., Zhao C.-L., Wang Z.-B.

Establishment of human hepatocellular carcinoma multidrug-resistance cell line (HepG2/Adm) and study apoptosis induced by low-frequency pulse ultrasound exposure.

Zhonghua Gan Zang Bing Za Zhi 12:95-98(2004)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

PubMed=16181800; DOI=10.1016/j.biocel.2005.07.010

Donohue T.M., Osna N.A., Clemens D.L.

Recombinant Hep G2 cells that express alcohol dehydrogenase and cytochrome P450 2E1 as a model of ethanol-elicited cytotoxicity.

Int. J. Biochem. Cell Biol. 38:92-101(2006)

PubMed=16935386; DOI=10.1016/j.jhep.2006.05.019

Sun D.-X., Nassal M.

Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus.

J. Hepatol. 45:636-645(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001

Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.

Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.

Biologicals 35:195-202(2007)

PubMed=19215227; DOI=10.1111/j.1349-7006.2009.01082.x; PMCID=PMC11158180

Kuwahara Y., Li L., Baba T., Nakagawa H., Shimura T., Yamamoto Y., Ohkubo Y., Fukumoto M.

Clinically relevant radioresistant cells efficiently repair DNA double-strand breaks induced by X-rays.

Cancer Sci. 100:747-752(2009)

PubMed=19751877; DOI=10.1016/j.humpath.2009.07.003

Lopez-Terrada D.H., Cheung S.-W., Finegold M.J., Knowles B.B.

Hep G2 is a hepatoblastoma-derived cell line.

Hum. Pathol. 40:1512-1515(2009)

PubMed=20069059; DOI=10.1155/2010/437143; PMCID=PMC2801507

Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.

Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.

J. Biomed. Biotechnol. 2010:437143.1-437143.18(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20228232; DOI=10.1124/dmd.109.031831; PMCID=PMC2879958

Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Drug Metab. Dispos. 38:988-994(2010)

PubMed=20937217; DOI=10.1170/149

Di Masi A., Viganotti M., Antoccia A., Magrelli A., Salvatore M., Azzalin G., Tosto F., Lorenzetti S., Maranghi F., Mantovani A., Macino G., Tanzarella C., Taruscio D.

Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta-catenin pathway, microRNA expression and protein expression profile.

Cell. Mol. Biol. 56:OL1299-OL1317(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17; PMCID=PMC3039570

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.

Initial characterization of the human central proteome.

BMC Syst. Biol. 5:17.1-17.13(2011)

PubMed=22278370; DOI=10.1074/mcp.M111.014050; PMCID=PMC3316730

Geiger T., Wehner A., Schaab C., Cox J., Mann M.

Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.

Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112; PMCID=PMC3589544

Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.

Dynamic DNA methylation across diverse human cell lines and tissues.

Genome Res. 23:555-567(2013)

PubMed=23505090; DOI=10.1002/hep.26402

Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z., Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.-C.

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218.1-2218.7(2013)

PubMed=24116068; DOI=10.1371/journal.pone.0075692; PMCID=PMC3792989

Weiskirchen R., Weimer J., Meurer S.K., Kron A., Seipel B., Vater I., Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.

Genetic characteristics of the human hepatic stellate cell line LX-2.

PLoS ONE 8:E75692-E75692(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311; PMCID=PMC4284350

Cevik D., Yildiz G., Ozturk M.

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

World J. Gastroenterol. 21:311-317(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26160117; DOI=10.1093/toxsci/kfv136; PMCID=PMC4583060

Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.

Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.

Toxicol. Sci. 147:412-424(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26825538; DOI=10.1016/j.jprot.2016.01.016

Wisniewski J.R., Vildhede A., Noren A., Artursson P.

In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes.

J. Proteomics 136:234-247(2016)

PubMed=27027780; DOI=10.1007/s10565-016-9316-2

Wu Y., Geng X.-C., Wang J.-F., Miao Y.-F., Lu Y.-L., Li B.

The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury.

Cell Biol. Toxicol. 32:37-59(2016)

PubMed=27329724; DOI=10.18632/oncotarget.10161; PMCID=PMC5216950

Watari K., Nishitani A., Shibata T., Noda M., Kawahara A., Akiba J., Murakami Y., Yano H., Kuwano M., Ono M.

Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.

Oncotarget 7:47403-47417(2016)

PubMed=27470094; DOI=10.1016/j.chroma.2016.07.042

Liu Z.-Y., Wang F.-J., Chen J., Zhou Y., Zou H.-F.

Modulating the selectivity of affinity absorbents to multi-phosphopeptides by a competitive substitution strategy.

J. Chromatogr. A 1461:35-41(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003; PMCID=PMC6309175

Shi J., Wang X.-W., Lyu L.-Y., Jiang H., Zhu H.-J.

Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.

Drug Metab. Pharmacokinet. 33:133-140(2018)

PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012

Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J., Lobinski R., Chavatte L.

Selenium-regulated hierarchy of human selenoproteome in cancerous and immortalized cells lines.

Biochim. Biophys. Acta 1862:2493-2505(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

Screening human cell lines for viral infections applying RNA-Seq data analysis.

PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30864654; DOI=10.1093/nar/gkz169; PMCID=PMC6486628

Zhou B., Ho S.S., Greer S.U., Spies N., Bell J.M., Zhang X.-L., Zhu X.-W., Arthur J.G., Byeon S., Pattni R., Saha I., Huang Y.-L., Song G., Perrin D., Wong W.H., Ji H.P., Abyzov A., Urban A.E.

Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2.

Nucleic Acids Res. 47:3846-3861(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001

Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Gastroenterology 157:760-776(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001; PMCID=PMC7505724

Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.

A pharmacogenomic landscape in human liver cancers.

Cancer Cell 36:179-193.e11(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31561354; DOI=10.3233/CH-199226; PMCID=PMC6918903

Schulz C., Kammerer S., Kupper J.-H.

NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies.

Clin. Hemorheol. Microcirc. 73:249-260(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)"